Company Overview and News

 
CES Energy Solutions Corp. Declares Cash Dividend and Provides Q3 Conference Call Details

2018-10-11 globenewswire
CALGARY, Alberta, Oct. 11, 2018 (GLOBE NEWSWIRE) -- CES Energy Solutions Corp. ("CES" or the “Company”) (TSX: CEU) (OTC – Nasdaq Intl: CESDF) is pleased to announce today that it will pay a cash dividend of $0.005 per common share on November 15, 2018 to the shareholders of record at the close of business on October 31, 2018.
CEU

 
CES Energy Solutions Corp. Declares Cash Dividend

2018-09-13 globenewswire
CALGARY, Alberta, Sept. 13, 2018 (GLOBE NEWSWIRE) -- CES Energy Solutions Corp. (“CES” or the “Corporation”) (TSX: CEU and OTC - Nasdaq Intl: CESDF) is pleased to announce today that it will pay a cash dividend $0.005 per common share on October 15, 2018 to the shareholders of record at the close of business on September 28, 2018.
CEU

 
CES Energy Solutions Corp. Reports Record Second Quarter Results, Declares Cash Dividend and Announces Management Changes

2018-08-09 globenewswire
CALGARY, Alberta, Aug. 09, 2018 (GLOBE NEWSWIRE) -- CES Energy Solutions Corp. ("CES" or the “Company”) (TSX: CEU) (OTC – Nasdaq Intl: CESDF) is pleased to report on its financial and operating results for the three and six months ended June 30, 2018. Further, CES announced today that it will pay a cash dividend of $0.005 per common share on September 14, 2018 to the shareholders of record at the close of business on August 31, 2018.
CEU

 
CES Energy Solutions Corp. Announces Acceptance of Previously Announced Normal Course Issuer Bid, Declares Cash Dividend and Provides Q2 Conference Call Details

2018-07-12 globenewswire
CALGARY, Alberta, July 12, 2018 (GLOBE NEWSWIRE) -- CES Energy Solutions Corp. (“CES” or the “Corporation”) (TSX:CEU) (OTC:CESDF) is pleased to announce that the Toronto Stock Exchange (the “TSX”) has accepted CES’s notice of its intention to implement a normal course issuer bid (“NCIB”). CES’s Board of Directors and management believe that the market price of CES’s common shares do not reflect their underlying value.
CESDF CEU

 
CES Energy Solutions Corp. Announces Voting Results of the Election of Directors

2018-06-14 globenewswire
CALGARY, Alberta, June 14, 2018 (GLOBE NEWSWIRE) -- CES Energy Solutions Corp. (“CES” or the “Corporation”) (TSX:CEU) (OTC:CESDF) is pleased to announce the results of the matters to be voted on at the annual general meeting of shareholders held on June 14, 2018 (the “Meeting”). Based on the proxies received and on a ballot conducted at the Meeting, the following individuals, being the eight nominees listed in the management information circular of the Corporation dated May 1, 2018 (the “Circular”), were elected as directors of the Corporation until the next annual shareholders’ meeting:
CESDF CEU

 
CES Energy Solutions Corp. Announces Intent to Implement a Normal Course Issuer Bid and Doubling of Monthly Cash Dividend

2018-06-14 globenewswire
CALGARY, Alberta, June 14, 2018 (GLOBE NEWSWIRE) -- CES Energy Solutions Corp. (“CES” or the “Corporation”) (TSX:CEU) (OTC:CESDF) is pleased to announce its intent to implement a normal course issuer bid (“NCIB”) and the approval by the Board of Directors of the Corporation to double its monthly cash dividend to $0.005 per common share. The increased cash dividend of $0.005 per common share will be paid on July 13, 2018 to the shareholders of record at the close of business on June 29, 2018.
CESDF CEU

1
CES Energy Solutions Corp. Reports Record Revenue for the First Quarter Ended March 31, 2018 and Declares Cash Dividend

2018-05-10 globenewswire - 1
CALGARY, Alberta, May 10, 2018 (GLOBE NEWSWIRE) -- CES Energy Solutions Corp. ("CES" or the “Company”) (TSX:CEU) (OTC – Nasdaq Intl:CESDF) is pleased to report on its financial and operating results for the three months ended March 31, 2018. Further, CES announced today that it will pay a cash dividend of $0.0025 per common share on June 15, 2018 to the shareholders of record at the close of business on May 31, 2018.
CEU

1
UPDATE - Nasdaq Hosted 3rd Nasdaq International Designation Virtual Investor Conference

2018-04-18 globenewswire
NEW YORK, April 18, 2018 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq:NDAQ) announced the conclusion of its 3rd Nasdaq International Designation Virtual Investor Conference on April 4, 2018. Nasdaq welcomed select Nasdaq International Designation Member Companies to present their current state of business to a broad audience including potential investors. The Conference also provided individual and institutional investors an opportunity to engage with CEOs, CFOs, and IROs from a wide range of sectors globally.
AJX CEU NMT NHVCF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TSX:CEU / Canadian Energy Svcs and on message board site Silicon Investor.

Regeneron Pharmaceuticals Regeneron Pharmaceuticals Regeneron Pharmaceuticals INO - Inovio Pharmaceuticals - A NYSE Small-Cap INO - Inovio Pharmaceuticals - A NYSE Small-Cap INO - Inovio Pharmaceuticals - A NYSE Small-Cap
Ionis Pharmaceuticals (IONS) Ionis Pharmaceuticals (IONS) Ionis Pharmaceuticals (IONS) GWPH GW Pharmaceuticals board GWPH GW Pharmaceuticals board GWPH GW Pharmaceuticals board
Madrigal Pharmaceuticals Madrigal Pharmaceuticals Madrigal Pharmaceuticals ACADIA Pharmaceuticals Inc (ACAD) ACADIA Pharmaceuticals Inc (ACAD) ACADIA Pharmaceuticals Inc (ACAD)
Clinuvel Pharmaceuticals Ltd Clinuvel Pharmaceuticals Ltd Clinuvel Pharmaceuticals Ltd Rigel Pharmaceuticals, Inc. (RIGL) Rigel Pharmaceuticals, Inc. (RIGL) Rigel Pharmaceuticals, Inc. (RIGL)
TTPH, Tetraphase Pharmaceuticals TTPH, Tetraphase Pharmaceuticals TTPH, Tetraphase Pharmaceuticals Arena Pharmaceuticals (ARNA) Arena Pharmaceuticals (ARNA) Arena Pharmaceuticals (ARNA)